Abstract
Background and Aim: EBVaGC represents a distinct molecular subtype of gastric cancer, accounting for approximately 10% of all cases. Among EBV-encoded antigens, EBNA1 and BZLF1 have emerged as promising targets for vaccine development due to their critical roles in viral persistence and lytic reactivation, respectively. In this study, we rationally designed multi-epitope vaccine peptide candidate targeting these key proteins in EBVaGC. Results: A large number of CTL, HTL, and LBL epitopes were identified from both proteins. Subsequently, the top three epitopes in each category epitopes for each precursor protein were selected according to percentile rank, antigenicity, immunogenicity, non-allergenicity, and non-toxicity to further use in constructs. The selected HTL epitopes also found could induce cytokines responses such as IFN-γ, IL-2, IL-4, and IL-10. A population coverage analysis reveal that the selected epitopes showed a high global population coverage of 97.25%, indicating broad applicability across diverse populations. Furthermore, in this study three MEVP constructs were designed and exhibiting favorable antigenic, non-allergenic, and non-toxic properties. Among them, MEVPC demonstrated superior physicochemical characteristics, including a lower instability index and a higher aliphatic index, supported by better structural validation (ProSA Z-score, ERRAT, and Ramachandran plot). Molecular docking analysis revealed that all constructs bind effectively to TLR-9, with MEVPC showing the strongest docking score (−131.5±2.0 kcal/mol). However, MM/GBSA analyses indicated that MEVPA–TLR9 had the highest binding affinity (−62.15 kcal/mol). Contrarily, molecular dynamics simulations confirmed that MEVPA–TLR9 was the most stable complex (RMSD ~1.0–1.4 nm), whereas MEVPC exhibited high instability despite having the highest number of hydrogen bonds. Immune simulation of the MEVPC hypothesis generated strong and sustained immune responses, including elevated IgG1/IgG2, IFN-γ, IL-4, and memory T- and B-cell formation. Conclusion: MEVPA shows the highest structural stability, while MEVPC demonstrates powerful characteristics and strong immunogenic potential, supporting their promise as EBVaGC vaccine candidates